Company Profile

LogicBio Therapeutics, Inc. is a clinical-stage genetic medicine company. It is focused on genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. Its genome editing platform, GeneRide, is an approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid repair process, potentially to durable therapeutic protein expression levels. Its gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate, LB-001, for the treatment of methylmalonic acidemia (MMA) in pediatric patients. LB-001 is designed to introduce a functional copy of the methylmalonyl-CoA mutase (MUT) gene into the genome of MMA patients. It is developing LB-401 for the treatment of hereditary tyrosinemia type 1 (HT1). The Company is developing LB-301 for the treatment of Crigler-Najjar syndrome (CN).

Employees

Sector

Pharmaceuticals

More about the company

23-01-03	CANbridge Pharmaceuticals Inc. Announces Update on Collaborations with the Umass Chan Medical School and with Logicbio Therapeutics	CI
22-11-21	LogicBio Therapeutics, Inc.(NasdaqGM:LOGC) dropped from S&P TMI Index	CI
22-11-16	LogicBio Therapeutics, Inc. Announces Management Changes	CI
22-11-16	AstraZeneca Unit Completes Acquisition of LogicBio Therapeutics	MT
22-11-16	LogicBio Therapeutics, Inc.(NasdaqGM:LOGC) dropped from NASDAQ Composite Index	CI
22-11-14	Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders.	CI
22-11-14	LogicBio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-11-14	Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q3 Revenue $2.7M	MT
22-11-14	Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q3 Loss $-0.18	MT
22-10-07	LogicBio Therapeutics, Inc. and CANbridge Care Pharma Hong Kong Limited Enter into the Amended and Restated Exclusive Research Collaboration, License and Option Agreement	CI
22-10-03	AstraZeneca Unit To Buy US Biotech LogicBio Therapeutics	MT
22-10-03	ADRs End Higher, ABB and AstraZeneca Trade Actively	DJ
22-10-03	Sector Update: Health Care Stocks Catching Up With Broader Market Gains	MT

22-08-22	Chardan Research Cuts Price Target on LogicBio Therapeutics to $2.50 From $4, Reiterates Buy Rating	MT
22-05-17	Chardan Capital Adjusts LogicBio Therapeutics' Price Target to $4 from $6, Keeps Buy Rating	MT
22-05-10	William Blair Upgrades LogicBio Therapeutics to Outperform From Market Perform	MT
22-02-03	William Blair Downgrades LogicBio Therapeutics to Market Perform From Outperform	MT
22-02-03	Chardan Cuts LogicBio Therapeutics' Price Target to $6 From $16 After FDA Places LB-001 Trial on Hold; Buy Rating Kept	MT

22-11-17	Alexion AstraZeneca Rare Disease Completes Acquisition of LogicBio Therapeutics	AQ
22-11-16	LOGICBIO THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
22-11-14	LogicBio Therapeutics : Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet - Definitive merger agreement with Alexion, AstraZeneca Rare Disease, to acquire LogicBio with transaction - Form 8-K	PU
22-11-14	LOGICBIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
22-11-14	LOGICBIO THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)	AQ

22-10-04	Bolsa de Madrid: El mercado intenta una nueva partitura
22-10-04	EN DIRECT DES MARCHES : Saint-Gobain, Atos, M6, Kaufman, Aston Martin, Nestlé, Pfizer, Sika...
22-10-04	Le marché essaie une nouvelle partition

Manager	Title	Age	Since
Frédéric Chéreau CEO	Chief Executive Officer	59	2016-03-31
Marie Payton COO	Chief Operating Officer	-	2019-03-31
Matthias Hebben CTO	Chief Tech/Sci/R&D Officer	-	2019-01-31

LogicBio Therapeutics, Inc. Stock

Stocks

LOGC

US54142F1021

Pharmaceuticals

Latest news : LogicBio Therapeutics, Inc.

Analysts' recommendations : LogicBio Therapeutics, Inc.

Press Releases : LogicBio Therapeutics, Inc.

News in other languages : LogicBio Therapeutics, Inc.

Quotes and Performance

Managers and Directors : LogicBio Therapeutics, Inc.

Latest insider transactions

Other Pharmaceuticals

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/16/22	Richard Moscicki	Issuer sale	Chairman	16,416	0.0498%
11/16/22	Mark A. Kay	Issuer sale	Founder	950,761	2.8844%
11/16/22	J. Goater	Issuer sale	Director	12,500	0.0379%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LOGICBIO THERAPEUTICS, INC.	+0.49%	-.--%	-	-	68.23M
ELI LILLY AND COMPANY	-0.04%	-1.40%	+57.16%	+108.15%	1,034B
JOHNSON & JOHNSON	+1.17%	+4.76%	+56.42%	+73.50%	663B
ABBVIE INC.	-0.58%	+0.80%	+22.82%	+75.58%	462B
ROCHE HOLDING AG	+2.09%	-2.06%	+32.28%	+37.41%	344B
NOVARTIS AG	0.00%	+5.36%	+27.40%	+46.97%	307B
ASTRAZENECA PLC	+1.42%	+0.26%	-0.52%	+13.51%	251B
AMGEN INC.	+0.29%	+1.63%	+56.46%	+73.00%	239B
NOVO NORDISK A/S	-0.03%	+2.13%	-17.30%	-53.65%	207B
GILEAD SCIENCES, INC.	+1.08%	+1.59%	+33.83%	+97.29%	186B
Average	+0.53%	+0.33%	+29.84%	+52.42%	410.37B
Weighted average by Cap.	+0.33%	+0.40%	+38.63%	+67.86%